| Overview |
| bsm-51087M |
| C-rel (8C2) Monoclonal Antibody |
| WB, IF |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| This REL monoclonal antibody is generated from mouse immunized with REL recombinant protein. |
| Monoclonal |
| 8C2 |
| IgG2b |
| 0.5ug/ul |
| Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C for 12 months. |
| Target |
| 5966 |
| Q04864 |
| C-Rel; Proto-oncogene c-Rel; REL |
| Proto-oncogene that may play a role in differentiation and lymphopoiesis. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The NF-kappa-B heterodimer RELA/p65-c-Rel is a transcriptional activator. |
| Application Dilution |
| WB |
1:300-5000 |
| IF |
|
Powered by Bioz